...Hello colleagues. My name is Hiroyuki Okuzawa, and I am the President and CEO of Daiichi Sankyo. Thank you for joining our briefing session focused on the highlights of our presentations at ASCO 2024. We have been making endeavors to transform cancer treatment with DXd ADCs that are our unique and innovative technology platform. It is my pleasure to share with you another major achievement for ER HER2 today. Two years ago, we presented DESTINY-Breast04 study data here at ASCO, which revealed that ER HER2 could contribute to breast cancer patients who were previously categorized as HER2 negative. Based on the outcome from the study, ER HER2 pioneered a new patient segment HER2 low breast cancer. Furthermore, yesterday, we presented data from DESTINY-Breast06 study, which expands the treatment opportunity for ER HER2 to earlier line of HER2 low breast cancer and moreover, to HER2 ultra-low breast cancer. We are developing other DXd ADCs such as Dato-DXd, HER3-DXd, I-DXd and DS-6000. We also...
